Uncomplicating the futureSM
 
Search

Healthcare Professionals

    Print page  

Clinical Benefits

SEPRAFILM® is proven to reduce post-operative adhesions and related complications. It has been studied in more than 4,000 patients and in 20 published clinical reports.1

Incidence of Reoperative Intestinal Obstruction

Reduction in Reoperative Adhesive Small Bowel Obstruction

In a prospective, randomized, controlled, blinded, multicenter study of patients receiving SEPRAFILM during intestinal resection, SEPRAFILM reduced reoperation required for adhesive SBO by 47% relative to untreated controls.2

Reduction in Reoperative Complexity

In a series of prospective clinical studies in which SEPRAFILM was placed at the initial procedure, SEPRAFILM reduced adhesions observed at subsequent surgery, resulting in:

  • Fewer inadvertent injuries3
  • Less operative time4
  • Reduced blood loss4
  • Easier ileostomy reversal3

Reduction in Adhesions and Complexity at Repeat C-Section

In a study of patients receiving SEPRAFILM at primary C-section, SEPRAFILM significantly reduced adhesions, resulting in decreased procedure and delivery times at repeat C-section.4

1. Data on File, Genzyme Corporation
 
2. Fazio VW, Cohen Z, Fleshman JW, et al. Reduction in adhesive small-bowel obstruction by Seprafilm Adhesion Barrier after intestinal resection. Dis Colon Rectum. 2005;49:1-11.
 
3. Tang C-L, Seow-Choen F, Fook-Chong S, Eu K-W. Bioresorbable adhesion barrier facilitates early closure of the defunctioning ileostomy after rectal excision. Dis Colon Rectum. 2003;46:1200-1207.
 
3. Tang C-L, Seow-Choen F, Fook-Chong S, Eu K-W. Bioresorbable adhesion barrier facilitates early closure of the defunctioning ileostomy after rectal excision. Dis Colon Rectum. 2003;46:1200-1207.
 
4. Fushiki H, Ikoma T, Kobayashi H, Yoshimoto H. Efficacy of SEPRAFILM as an Adhesion Barrier in Cesarean Sections. Obstetric and Gynecological Treatment [Japanese]. 2005;91(5):557-561.
 
4. Fushiki H, Ikoma T, Kobayashi H, Yoshimoto H. Efficacy of SEPRAFILM as an Adhesion Barrier in Cesarean Sections. Obstetric and Gynecological Treatment [Japanese]. 2005;91(5):557-561.
 
4. Fushiki H, Ikoma T, Kobayashi H, Yoshimoto H. Efficacy of SEPRAFILM as an Adhesion Barrier in Cesarean Sections. Obstetric and Gynecological Treatment [Japanese]. 2005;91(5):557-561.
 

 

Surgeons discuss
adhesions and their potential impact on patients
Aimee's Story
See what patients say about SEPRAFILM
 

Indication

Seprafilm® Adhesion Barrier is indicated for the reduction of post-surgical adhesions in patients undergoing abdominal or pelvic laparotomy.

Important Safety Information

Seprafilm should not be wrapped around an intestinal anastomosis as such usage may result in increased anastomotic leak related events, such as abscess or peritonitis. The safety and effectiveness of Seprafilm has not been established in combination with other adhesion prevention products and/or in surgical procedures not within the abdominopelvic cavity. The safety and effectiveness of Seprafilm has also not been evaluated in cases of pregnancy, malignancy, or frank infection. The type and frequency of adverse events reported are consistent with events typically seen following abdominopelvic surgery when used as directed.

Please see full prescribing information.

Terms and Conditions of Use | Privacy Policy | Contact Us | This site is intended for United States residents only © 2002-2010 Genzyme Corporation. All rights reserved. Seprafilm and Genzyme are registered trademarks of Genzyme Corporation. genzyme logo